Bristol Myers Squibb

News

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

News

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.

News

Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.